MX2020005525A - Tratamientos con ligandos de proteína 2 similar a lantionina c y células preparadas con estos. - Google Patents

Tratamientos con ligandos de proteína 2 similar a lantionina c y células preparadas con estos.

Info

Publication number
MX2020005525A
MX2020005525A MX2020005525A MX2020005525A MX2020005525A MX 2020005525 A MX2020005525 A MX 2020005525A MX 2020005525 A MX2020005525 A MX 2020005525A MX 2020005525 A MX2020005525 A MX 2020005525A MX 2020005525 A MX2020005525 A MX 2020005525A
Authority
MX
Mexico
Prior art keywords
protein
lanthionine
therapies
ligands
compounds
Prior art date
Application number
MX2020005525A
Other languages
English (en)
Inventor
Josep Bassaganya-Riera
Andrew Leber
Raquel Hontecillas
Original Assignee
Landos Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Landos Biopharma Inc filed Critical Landos Biopharma Inc
Publication of MX2020005525A publication Critical patent/MX2020005525A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/20—Animal model comprising regulated expression system
    • A01K2217/206—Animal model comprising tissue-specific expression system, e.g. tissue specific expression of transgene, of Cre recombinase
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2312—Interleukin-12 (IL-12)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/385—Hormones with nuclear receptors of the family of the retinoic acid recptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Environmental Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se proporcionan compuestos que se dirigen a la vía de la proteína 2 similar a lantionina sintetasa C y a células, tales como células inmunitarias, preparadas in vitro con los compuestos. Los compuestos y las células se pueden usar para tratar una cantidad de afecciones, que incluyen enfermedades infecciosas, trastornos hiperproliferativos, errores congénitos del metabolismo, enfermedades inmunometabólicas crónicas, enfermedades autoinmunitarias, rechazo al trasplante de órgano, trastornos inflamatorios y dolor crónico, entre otros.
MX2020005525A 2017-11-30 2018-11-16 Tratamientos con ligandos de proteína 2 similar a lantionina c y células preparadas con estos. MX2020005525A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762592692P 2017-11-30 2017-11-30
PCT/US2018/061588 WO2019108418A1 (en) 2017-11-30 2018-11-16 Therapies with lanthionine c-like protein 2 ligands and cells prepared therewith

Publications (1)

Publication Number Publication Date
MX2020005525A true MX2020005525A (es) 2020-10-28

Family

ID=64664467

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020005525A MX2020005525A (es) 2017-11-30 2018-11-16 Tratamientos con ligandos de proteína 2 similar a lantionina c y células preparadas con estos.

Country Status (13)

Country Link
US (2) US11197891B2 (es)
EP (1) EP3717633A1 (es)
JP (1) JP2021503936A (es)
KR (1) KR20200090873A (es)
CN (1) CN111511904A (es)
AU (1) AU2018374767A1 (es)
BR (1) BR112020010983A2 (es)
CA (1) CA3083442A1 (es)
CL (1) CL2020001422A1 (es)
EA (1) EA202091325A1 (es)
IL (1) IL274989A (es)
MX (1) MX2020005525A (es)
WO (1) WO2019108418A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3927427B1 (en) 2019-12-20 2024-02-07 Nimmune Biopharma, Inc. Lanthionine c-like protein 2 ligands, cells prepared therewith, and therapies using same
WO2021174024A1 (en) 2020-02-28 2021-09-02 First Wave Bio, Inc. Methods of treating iatrogenic autoimmune colitis
CN114195806A (zh) * 2020-09-18 2022-03-18 上海医药集团股份有限公司 一种羰基杂环类化合物及其应用
WO2022087146A1 (en) * 2020-10-22 2022-04-28 Landos Biopharma, Inc. Lancl ligands
WO2022098644A1 (en) 2020-11-03 2022-05-12 Landos Biopharma, Inc. Crystalline forms of piperazine-1,4-diylbis((6-(1h-benzoi[d]imidazo-2-yl)pyridin-2yl)methanone) as lancl2 modulators
EP4225315A2 (en) 2020-11-19 2023-08-16 Nimmune Biopharma, Inc. Compounds, compositions, and methods for treating inflammatory or immune-mediated conditions of surface tissues
WO2022127774A1 (zh) * 2020-12-15 2022-06-23 成都百裕制药股份有限公司 吡啶衍生物及其在医药上的应用

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0282643A3 (en) 1986-11-22 1990-08-22 The Green Cross Corporation Use of pharmaceutical compositions comprising cyclohexane derivatives in the treatment or prevention of peptic ulcers
US5633388A (en) 1996-03-29 1997-05-27 Viropharma Incorporated Compounds, compositions and methods for treatment of hepatitis C
ATE288909T1 (de) 1997-12-24 2005-02-15 Nikem Research Srl Indolderivate verwendbar zur behandlung von u.a. osteoporosis
GB9914825D0 (en) 1999-06-24 1999-08-25 Smithkline Beecham Spa Novel compounds
GB0112834D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
TW200406413A (en) 2002-06-26 2004-05-01 Glaxo Group Ltd Compounds
US20070078120A1 (en) 2003-10-21 2007-04-05 Hitoshi Ban Novel piperidine derivative
JPWO2005082905A1 (ja) 2004-02-26 2007-08-02 協和醗酵工業株式会社 二環性複素環化合物
US7674907B2 (en) 2004-07-23 2010-03-09 Amgen Inc. Furanopyridine derivatives and methods of use
EP1814393A4 (en) * 2004-11-04 2010-02-03 Med College Georgia Res Inst TOLEROGENIC VACCINE AND METHOD THEREOF
US7919487B2 (en) 2004-11-10 2011-04-05 Synta Pharmaceuticals Corporation Heteroaryl compounds
CA2596013C (en) 2005-01-28 2012-06-05 Daewoong Pharmaceutical Co., Ltd. Benzoimidazole derivatives and pharmaceutical composition comprising the same
GB0508314D0 (en) 2005-04-25 2005-06-01 Novartis Ag Organic compounds
CN100434419C (zh) 2005-06-03 2008-11-19 中国人民解放军军事医学科学院毒物药物研究所 单环多取代饱和环已酮类化合物及其制备方法和用途
US7754724B2 (en) 2005-06-30 2010-07-13 Dow Agrosciences Llc N-substituted piperazines
WO2007019345A1 (en) 2005-08-04 2007-02-15 Sirtris Pharmaceuticals, Inc. Imidazopyridine derivatives as sirtuin modulating agents
UY29825A1 (es) 2005-10-03 2007-05-31 Astrazeneca Ab Derivados sustituidos de 3h-imidazol-(4,5 b (beta))piridina-2-il benzoatos y benzamidas, composiciones farmacéuticas que los contienen y aplicaciones
US20070203236A1 (en) 2006-01-11 2007-08-30 Smith Jeffrey W Novel antagonists of the human fatty acid synthase thioesterase
US7741367B2 (en) 2006-02-08 2010-06-22 Virginia Tech Intellectual Properties, Inc. Method of using abscisic acid to treat diseases and disorders
US8367727B2 (en) * 2006-02-08 2013-02-05 Virginia Tech Intellectual Properties, Inc. Method of using abscisic acid to treat diseases and disorders
JP2008056615A (ja) 2006-08-31 2008-03-13 Fujifilm Corp ビニルエチニルアリールカルボン酸類、その製造方法及びそれを用いた熱架橋性化合物の製造方法
JP2010510254A (ja) 2006-11-24 2010-04-02 ワラタ ファーマシューティカルズ， インコーポレイテッド アルツハイマー病および関連の神経変性疾患のための併用処置
JP2010513519A (ja) 2006-12-22 2010-04-30 ミレニアム・ファーマシューティカルズ・インコーポレイテッド キナーゼインヒビター活性を有するある種のピラゾリン誘導体
MY146643A (en) 2007-07-30 2012-09-14 Dae Woong Pharma Novel benzoimidazole derivatives and pharmaceutical composition comprising the same
JP2011505341A (ja) 2007-11-21 2011-02-24 デコード ジェネティクス イーエイチエフ 炎症性、心血管およびｃｎｓ障害を治療するビアリールｐｄｅ４抑制剤
EP2674417A3 (en) 2007-11-21 2014-04-09 Decode Genetics EHF Biaryl PDE4 inhibitors for treating inflammation
CA2647900C (en) 2008-12-23 2017-05-16 National Research Council Of Canada Inhibitors of a 9-cis-epoxycarotenoid dioxygenase
CN102459227B (zh) 2009-04-17 2014-08-20 詹森药业有限公司 Ccr2的4-氮杂环丁烷基-1-苯基-环己烷拮抗剂
DE102009057167A1 (de) 2009-12-05 2011-06-09 Merck Patent Gmbh Elektronische Vorrichtung enthaltend Metallkomplexe
EP2567225B1 (en) 2010-05-04 2019-10-02 Virginia Tech Intellectual Properties, Inc. Lanthionine synthetase component c-like proteins as molecular targets for preventing and treating diseases and disorders
WO2011150160A2 (en) 2010-05-26 2011-12-01 Virginia Tech Intellectual Properties, Inc. Method of preventing and treating inflammatory diseases and disorders with abscisic acid
TW201211027A (en) 2010-06-09 2012-03-16 Janssen Pharmaceutica Nv Cyclohexyl-azetidinyl antagonists of CCR2
US8518969B2 (en) 2010-06-17 2013-08-27 Janssen Pharmaceutica Nv Cyclohexyl-azetidinyl antagonists of CCR2
CA2861939A1 (en) 2011-12-30 2013-07-04 Centaurus Biopharma Co., Ltd. Novel arylalkene derivatives and use thereof as selective estrogen receptor modulators
JP6499306B2 (ja) 2014-10-24 2019-04-10 ランドス バイオファーマ インコーポレイテッド ランチオニンシンテターゼｃ様２系治療薬

Also Published As

Publication number Publication date
JP2021503936A (ja) 2021-02-15
CN111511904A (zh) 2020-08-07
US11197891B2 (en) 2021-12-14
IL274989A (en) 2020-07-30
EA202091325A1 (ru) 2020-08-28
AU2018374767A1 (en) 2020-06-25
CL2020001422A1 (es) 2021-07-30
EP3717633A1 (en) 2020-10-07
BR112020010983A2 (pt) 2020-11-17
WO2019108418A1 (en) 2019-06-06
US20190160100A1 (en) 2019-05-30
US20220072044A1 (en) 2022-03-10
KR20200090873A (ko) 2020-07-29
CA3083442A1 (en) 2019-06-06

Similar Documents

Publication Publication Date Title
MX2020005525A (es) Tratamientos con ligandos de proteína 2 similar a lantionina c y células preparadas con estos.
MX2023001226A (es) Anticuerpos anti-lag-3.
PH12018500707A1 (en) Anti-human cd19 antibodies with high affinity
WO2014151960A3 (en) Methods for controlling t cell proliferation
PH12016502447A1 (en) Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
MX370018B (es) Metodos mejorados para la elaboracion de terapias celulares adoptivas.
WO2015048348A3 (en) Compositions and formulations for increasing renal function and treatment and prevention of renal diseases, and methods of production and use thereof
MX2019007357A (es) Anticuerpos que se unen especificamente a il-15 humana y usos de estos.
NZ756678A (en) Anti-lag-3 antibodies and uses thereof
MX2023007496A (es) Antifolatos poliglutamados y sus usos.
MX2015016111A (es) Anticuerpos anti-b7-h5 y sus usos.
MX2017007293A (es) Animales no humanos que tienen un gen del grupo de diferenciacion 47 humanizado.
MX370720B (es) Anticuerpos anti-gdf15.
MY155137A (en) Compounds that expand hematopoietic stem cells
WO2014134084A3 (en) Phf20 and jmjd3 compositions and methods of use in cancer immunotherapy
EP3943092A3 (en) Compositions for use in inducing differentiation of human brown adipocyte progenitors
MX2020005849A (es) Células madre y progenitoras hematopoyéticas humanas cd34+ modificadas con crispr-cas9 y sus usos.
MX2021003797A (es) Terapias inmunoablativas.
EP4275746A3 (en) Extracellular vesicles derived from osteoblastic lineage cells for therapeutic and diagnostic use
PH12020551619A1 (en) Anti-trem-1 antibodies and uses thereof
MX2021005956A (es) Composiciones biologicas secas y metodos de las mismas.
WO2012102937A3 (en) Benz imidazole compounds that expand hematopoietic stem cells
IN2014DN08964A (es)
MX2021005245A (es) Composiciones de oligosacaridos y metodos de uso de las mismas.
IL287010A (en) Preparations and methods for cryogenic freezing of immune cells